Ivabradine Shows Promise as Tx for Hyperadrenergic POTS

Further study needed in other POTS subtypes In patients with hyperadrenergic postural orthostatic tachycardia syndrome (POTS), one month of treatment with ivabradine brought about significant improvements in several parameters, including heart rate, quality of life (QOL), and plasma norepinephrine (NE) levels, according to results from a recent study published in the Journal of the American

Ivabradine for the Treatment of Postural Orthostatic Tachycardia

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

PDF) Cognitive Dysfunction in Postural Tachycardia Syndrome.

Karsten HEUSSER, Senior Physician Scientist

Acute hyperhidrosis and postural tachycardia in a COVID-19 patient

PDF) Ivabradine in Postural Orthostatic Tachycardia Syndrome: A

Ivabradine in children with postural orthostatic tachycardia

Randomized Trial of Ivabradine in Patients With Hyperadrenergic

Postural Tachycardia Syndrome and COVID-19: Focus on Ivabradine

Hyperadrenergic POTS: Clinical presentation and mgmt

Dysautonomia and pots

The Postural Tachycardia Syndrome (POTS): pathophysiology

Cracking the Code of Dysautonomia: POTS, Orthostatic Hypotension

Cracking the Code of Dysautonomia: POTS, Orthostatic Hypotension, and Heart Health